EXACT SCIENCES ($NASDAQ:EXAS) reported total revenue of USD 622.1 million for the quarter ending June 30 2023, representing a year-on-year increase of 19.3%. Net income for the quarter was USD -81.0 million, an improvement from the prior year’s corresponding loss of -166.1 million. The results were made public on August 1 2023.
Analysis – Exact Sciences Stock Intrinsic Value
GoodWhale conducted an analysis of EXACT SCIENCES‘s wellbeing and calculated the fair value of its share to be around $102.2 with their proprietary Valuation Line. The current price of EXACT SCIENCES stock is $96.4, which is undervalued by 5.7%. This presents a great opportunity to invest in the stock and benefit from potential gains if the market corrects itself and the stock goes up to the fair value. Moreover, investing in EXACT SCIENCES now may also yield long-term returns as it can provide a strong foundation for a diversified portfolio. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Exact Sciences. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Exact Sciences. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Exact Sciences. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Exact Sciences are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The market for cancer diagnostics is highly competitive. Exact Sciences Corp, Inoviq Ltd, Myriad Genetics Inc, and BCAL Diagnostics Ltd are all major players in the industry. Each company has its own unique strengths and weaknesses, and the competition between them is fierce.
Inoviq Ltd has a market cap of 55.21M as of 2022. The company’s Return on Equity for the same year is -13.68%.
Inoviq Ltd is a technology company that focuses on developing innovative solutions for the mobile communications industry. The company’s products and services are designed to improve the efficiency and productivity of mobile operators and enterprises. Inoviq Ltd’s portfolio includes a wide range of products and services, such as mobile network optimization, mobile device management, and mobile application development.
Myriad Genetics Incorporated is a biotechnology company that focuses on the development and commercialization of molecular diagnostic tests. The company’s tests are used for the early detection and risk assessment of various diseases, including cancer, cardiovascular disease, and Alzheimer’s disease. Myriad Genetics Incorporated is headquartered in Salt Lake City, Utah.
EXACT SCIENCES reported total revenue of USD 622.1 million for the quarter ended June 30 2023, an increase of 19.3% year over year. This suggests that the company is making strides with its growth strategies, despite still recording a net loss for the period. Investors may want to pay close attention to EXACT SCIENCES’ future financials, as continued growth and profitability may be indicative of a sound investment opportunity.